Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban PK/PD in ESRD on Hemodialysis
NCT02289703Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time and 1 more. Started Jan 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02289703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289703.